• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

索拉非尼治疗伴门静脉癌栓的肝细胞癌完全病理缓解。

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

机构信息

Department of Digestive Surgery, Rouen University Hospital, 1 Rue de Germont, 76031 Rouen, France.

出版信息

World J Surg Oncol. 2013 Aug 2;11(1):171. doi: 10.1186/1477-7819-11-171.

DOI:10.1186/1477-7819-11-171
PMID:23914915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3735470/
Abstract

Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.

摘要

索拉非尼是一种分子靶向治疗药物，用于治疗 Child-Pugh A 级的晚期肝细胞癌（HCC）患者的姑息治疗。我们描述了一例患者的病例，该患者左肝有大肝癌并伴有门静脉血栓形成（PVT）。索拉非尼治疗 9 个月后，重新评估显示肿瘤体积缩小，门静脉再通。行左肝外侧叶切除术，术后病理显示肿瘤完全坏死。索拉非尼可以使肝硬化患者的 HCC 降期，从而允许进一步进行手术切除。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/6dcdea88634c/1477-7819-11-171-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/dd44f03a3dac/1477-7819-11-171-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/3630fad1fe8a/1477-7819-11-171-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/b13b311a5d29/1477-7819-11-171-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/6dcdea88634c/1477-7819-11-171-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/dd44f03a3dac/1477-7819-11-171-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/3630fad1fe8a/1477-7819-11-171-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/b13b311a5d29/1477-7819-11-171-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e10/3735470/6dcdea88634c/1477-7819-11-171-4.jpg

相似文献

1
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.索拉非尼治疗伴门静脉癌栓的肝细胞癌完全病理缓解。
World J Surg Oncol. 2013 Aug 2;11(1):171. doi: 10.1186/1477-7819-11-171.
2
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.索拉非尼诱导晚期肝细胞癌伴多发肺转移和静脉瘤栓实现根治性切除的完全病理缓解。
Clin J Gastroenterol. 2015 Oct;8(5):300-5. doi: 10.1007/s12328-015-0594-7. Epub 2015 Aug 7.
3
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.索拉非尼单药治疗晚期肝细胞癌合并门静脉癌栓的疗效观察。
Gut Liver. 2013 Nov;7(6):696-703. doi: 10.5009/gnl.2013.7.6.696. Epub 2013 Aug 14.
4
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.索拉非尼用于既往有手术史且合并门静脉肿瘤血栓形成的中国不可切除肝细胞癌患者的疗效评估：GIDEON研究数据的亚组分析
Tumour Biol. 2017 Mar;39(3):1010428317695030. doi: 10.1177/1010428317695030.
5
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.与经动脉化疗栓塞术或索拉非尼相比，肝切除术治疗伴有门静脉癌栓的肝细胞癌的生存结局。
Clin Mol Hepatol. 2016 Mar;22(1):160-7. doi: 10.3350/cmh.2016.22.1.160. Epub 2016 Mar 28.
6
Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection.索拉非尼治疗有可能在肝切除术前降低晚期肝细胞癌的分期。
Per Med. 2020 Mar;17(2):83-87. doi: 10.2217/pme-2018-0114. Epub 2020 Mar 11.
7
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.索拉非尼联合经动脉化疗栓塞术治疗不可切除肝细胞癌的完全缓解
World J Gastroenterol. 2016 Nov 14;22(42):9445-9450. doi: 10.3748/wjg.v22.i42.9445.
8
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.门静脉主干癌栓性肝细胞癌的综合治疗
World J Gastroenterol. 2016 Apr 7;22(13):3632-43. doi: 10.3748/wjg.v22.i13.3632.
9
Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.索拉非尼联合奥沙利铂、5-氟尿嘧啶和亚叶酸钙经肝动脉灌注同步治疗伴有主要门静脉血栓形成的不可切除肝细胞癌的II期研究
Cardiovasc Intervent Radiol. 2018 May;41(5):734-743. doi: 10.1007/s00270-017-1874-z. Epub 2018 Jan 11.
10
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.选择性内放射治疗与索拉非尼治疗门静脉血栓形成的肝细胞癌的比较。
Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):635-43. doi: 10.1007/s00259-015-3210-7. Epub 2015 Oct 12.

引用本文的文献

1
Liver resection and transplantation in the era of checkpoint inhibitors.免疫检查点抑制剂时代的肝切除与肝移植
JHEP Rep. 2024 Aug 6;6(11):101181. doi: 10.1016/j.jhepr.2024.101181. eCollection 2024 Nov.
2
Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus.新辅助肝动脉灌注化疗后行肝切除术治疗伴有门静脉癌栓的肝细胞癌的生存获益
Front Pharmacol. 2023 Sep 19;14:1223632. doi: 10.3389/fphar.2023.1223632. eCollection 2023.
3
Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report.

本文引用的文献

1
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.索拉非尼治疗后行肝切除术治疗肝细胞癌的安全性：一项多中心病例匹配研究。
Ann Surg Oncol. 2013 Oct;20(11):3603-9. doi: 10.1245/s10434-013-3029-z. Epub 2013 May 29.
2
A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group.在三级转诊中心，手术治疗肝细胞癌的有效适应证和结果概览：是否符合 EASL/AASLD 建议？：HCC 东西研究组的一项观察性研究。
Ann Surg. 2013 May;257(5):929-37. doi: 10.1097/SLA.0b013e31828329b8.
3
VEGFR2抑制剂阿帕替尼治疗后“降期”晚期肝细胞癌的切除术：五例报告
Transl Cancer Res. 2020 Aug;9(8):4999-5007. doi: 10.21037/tcr-19-3019.
4
Neoadjuvant treatment strategies for hepatocellular carcinoma.肝细胞癌的新辅助治疗策略
World J Gastrointest Surg. 2021 Dec 27;13(12):1550-1566. doi: 10.4240/wjgs.v13.i12.1550.
5
Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation.肝移植中肝细胞癌降期的上限
Cancers (Basel). 2021 Dec 17;13(24):6337. doi: 10.3390/cancers13246337.
6
Complete Regression of Hepatocellular Carcinoma with Low Dose of Sorafenib.低剂量索拉非尼使肝细胞癌完全消退
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):756-757. doi: 10.1016/j.jceh.2021.06.012. Epub 2021 Jun 17.
7
Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment.改善肝癌伴门静脉癌栓患者肝切除术后的结局：治疗演进时代的探索。
World J Surg Oncol. 2021 Oct 26;19(1):313. doi: 10.1186/s12957-021-02425-w.
8
Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib.索拉非尼治疗后疾病快速进展，而regorafenib 治疗后疗效良好的情况下，行转化手术治疗晚期肝细胞癌的完全缓解。
Intern Med. 2021;60(13):2047-2053. doi: 10.2169/internalmedicine.5870-20. Epub 2021 Jul 1.
9
A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.辅助索拉非尼治疗肝癌切除术后疗效和安全性的荟萃分析。
World J Surg Oncol. 2021 Jun 10;19(1):168. doi: 10.1186/s12957-021-02280-9.
10
Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma.肝细胞癌的新辅助治疗和免疫治疗策略
Am J Cancer Res. 2020 Jun 1;10(6):1658-1667. eCollection 2020.
Liver resection after downstaging hepatocellular carcinoma with sorafenib.
索拉非尼使肝细胞癌降期后行肝切除术。
Int J Hepatol. 2011;2011:791013. doi: 10.4061/2011/791013. Epub 2011 Mar 20.
4
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.索拉非尼诱导局部晚期肝细胞癌完全消退，从而实现治愈性切除。
Liver Int. 2011 May;31(5):740-3. doi: 10.1111/j.1478-3231.2010.02441.x. Epub 2011 Jan 11.
5
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.索拉非尼诱导晚期肝细胞癌完全组织学缓解：一例报告
J Clin Oncol. 2011 Apr 20;29(12):e330-2. doi: 10.1200/JCO.2010.32.6785. Epub 2011 Jan 24.
6
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation.肝硬化和肝细胞癌患者肝移植评估中良性门静脉血栓形成诊断标准。
Liver Transpl. 2010 May;16(5):658-67. doi: 10.1002/lt.22044.
7
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性：一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
8
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
9
Design and endpoints of clinical trials in hepatocellular carcinoma.肝细胞癌临床试验的设计与终点
J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.
10
Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.四种血管特异性生长因子与人类肝细胞癌发生及门静脉癌栓形成的相关性
J Exp Clin Cancer Res. 2006 Sep;25(3):403-9.